Compare Abbott Laboratories (ABT) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Vanguard Ultra Short Bond ETF — how do they compare? Abbott Laboratories trades at $109.6 (market cap $187.95B), while Vanguard Ultra Short Bond ETF trades at $49.67. The key difference: Abbott Laboratories pays a 2.32% dividend while Vanguard Ultra Short Bond ETF pays none, and Abbott Laboratories is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABT | VUSB | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $136.62 | $50.03 |
52-Week Low | $82.57 | $49.60 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
VUSB trades at $49.66, up 0.04% on the day, with a bearish technical signal driven by moving averages and ADX readings. Recent dividends include $0.18 paid on July 6, 2026, and $0.17 scheduled for August 5, 2026. Financial ratios such as P/E and ROE are unavailable in the current data, limiting fundamental assessment.
The outlook is cautious due to bearish technical indicators and incomplete financial data. Risks include interest rate sensitivity, as highlighted by recent Fed commentary, and reliance on short-term bond performance. Investors should await updated financial disclosures for a clearer fundamental picture.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
